Last reviewed · How we verify
Matulane (PROCARBAZINE)
Matulane (Procarbazine) is a small molecule alkylating drug originally developed by SIGMA TAU and currently owned by Leadiant Biosci Inc. It was FDA approved in 1969 for the treatment of Hodgkin's disease. As an off-patent medication, it is not commercially available as a generic. Matulane works by interfering with the DNA replication process in cancer cells, ultimately leading to cell death. Key safety considerations include potential hepatotoxicity and myelosuppression.
At a glance
| Generic name | PROCARBAZINE |
|---|---|
| Sponsor | Leadiant Biosci Inc |
| Drug class | Alkylating Drug |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1969 |
Approved indications
- Hodgkin's disease
Boxed warnings
- WARNING It is recommended that MATULANE be given only by or under the supervision of a physician experienced in the use of potent antineoplastic drugs. Adequate clinical and laboratory facilities should be available to patients for proper monitoring of treatment.
Common side effects
- Pancytopenia
- Hepatic dysfunction
- Hemolytic anemia
- Bleeding tendencies
- Hepatitis
- Jaundice
- Stomatitis
- Hematemesis
- Melena
- Diarrhea
- Dysphagia
- Anorexia
Drug interactions
- almotriptan
- bupivacaine
- eletriptan
- entacapone
- frovatriptan
- furazolidone
- isocarboxazid
- mepivacaine
- naratriptan
- pargyline
- phenelzine
- procaine
Key clinical trials
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) (PHASE2)
- A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (PHASE2)
- LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma (EARLY_PHASE1)
- Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
- A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). (PHASE3)
- Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) (PHASE1,PHASE2)
- A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |